Oncodesign announces the acquisition of Bertin Pharma’s pharmaceutical and biotech services businesses

  • Oncodesign is expanding its service offering in immunology and infectious diseases
  • It is gaining additional capacity for studying the ADME1 profile of therapeutic molecules, in regulated bioanalysis and in biobanking
  • The acquisition will contribute to the Oncodesign group’s revenue growth from September 1, 2017 onwards